nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—prostate gland—urinary bladder cancer	0.037	0.307	CbGeAlD
Fosaprepitant—TACR1—smooth muscle tissue—urinary bladder cancer	0.0262	0.218	CbGeAlD
Fosaprepitant—TACR1—renal system—urinary bladder cancer	0.0252	0.209	CbGeAlD
Fosaprepitant—TACR1—female reproductive system—urinary bladder cancer	0.0202	0.168	CbGeAlD
Fosaprepitant—TACR1—lymph node—urinary bladder cancer	0.0118	0.0981	CbGeAlD
Fosaprepitant—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000989	0.00112	CcSEcCtD
Fosaprepitant—Haematuria—Methotrexate—urinary bladder cancer	0.000984	0.00112	CcSEcCtD
Fosaprepitant—Weight decreased—Epirubicin—urinary bladder cancer	0.00098	0.00111	CcSEcCtD
Fosaprepitant—Dyspnoea—Etoposide—urinary bladder cancer	0.00098	0.00111	CcSEcCtD
Fosaprepitant—Somnolence—Etoposide—urinary bladder cancer	0.000977	0.00111	CcSEcCtD
Fosaprepitant—Vomiting—Thiotepa—urinary bladder cancer	0.000973	0.00111	CcSEcCtD
Fosaprepitant—Infestation NOS—Epirubicin—urinary bladder cancer	0.000966	0.0011	CcSEcCtD
Fosaprepitant—Infestation—Epirubicin—urinary bladder cancer	0.000966	0.0011	CcSEcCtD
Fosaprepitant—Rash—Thiotepa—urinary bladder cancer	0.000965	0.0011	CcSEcCtD
Fosaprepitant—Dermatitis—Thiotepa—urinary bladder cancer	0.000964	0.0011	CcSEcCtD
Fosaprepitant—Headache—Thiotepa—urinary bladder cancer	0.000959	0.00109	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000958	0.00109	CcSEcCtD
Fosaprepitant—Decreased appetite—Etoposide—urinary bladder cancer	0.000956	0.00109	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000949	0.00108	CcSEcCtD
Fosaprepitant—Body temperature increased—Cisplatin—urinary bladder cancer	0.000949	0.00108	CcSEcCtD
Fosaprepitant—Fatigue—Etoposide—urinary bladder cancer	0.000948	0.00108	CcSEcCtD
Fosaprepitant—Stomatitis—Epirubicin—urinary bladder cancer	0.000942	0.00107	CcSEcCtD
Fosaprepitant—Pain—Etoposide—urinary bladder cancer	0.00094	0.00107	CcSEcCtD
Fosaprepitant—Constipation—Etoposide—urinary bladder cancer	0.00094	0.00107	CcSEcCtD
Fosaprepitant—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000939	0.00107	CcSEcCtD
Fosaprepitant—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000939	0.00107	CcSEcCtD
Fosaprepitant—Dysuria—Doxorubicin—urinary bladder cancer	0.000937	0.00107	CcSEcCtD
Fosaprepitant—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000933	0.00106	CcSEcCtD
Fosaprepitant—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000926	0.00105	CcSEcCtD
Fosaprepitant—Asthenia—Gemcitabine—urinary bladder cancer	0.000924	0.00105	CcSEcCtD
Fosaprepitant—Haematuria—Epirubicin—urinary bladder cancer	0.000921	0.00105	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000915	0.00104	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000915	0.00104	CcSEcCtD
Fosaprepitant—Pruritus—Gemcitabine—urinary bladder cancer	0.000911	0.00104	CcSEcCtD
Fosaprepitant—Nausea—Thiotepa—urinary bladder cancer	0.000909	0.00103	CcSEcCtD
Fosaprepitant—Urethral disorder—Methotrexate—urinary bladder cancer	0.000908	0.00103	CcSEcCtD
Fosaprepitant—Weight decreased—Doxorubicin—urinary bladder cancer	0.000907	0.00103	CcSEcCtD
Fosaprepitant—Feeling abnormal—Etoposide—urinary bladder cancer	0.000906	0.00103	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000899	0.00102	CcSEcCtD
Fosaprepitant—Pruritus—Fluorouracil—urinary bladder cancer	0.000895	0.00102	CcSEcCtD
Fosaprepitant—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000894	0.00102	CcSEcCtD
Fosaprepitant—Infestation—Doxorubicin—urinary bladder cancer	0.000894	0.00102	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000886	0.00101	CcSEcCtD
Fosaprepitant—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000884	0.00101	CcSEcCtD
Fosaprepitant—Bradycardia—Epirubicin—urinary bladder cancer	0.000883	0.001	CcSEcCtD
Fosaprepitant—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000881	0.001	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000876	0.000996	CcSEcCtD
Fosaprepitant—Urticaria—Etoposide—urinary bladder cancer	0.000873	0.000993	CcSEcCtD
Fosaprepitant—Stomatitis—Doxorubicin—urinary bladder cancer	0.000871	0.000991	CcSEcCtD
Fosaprepitant—Abdominal pain—Etoposide—urinary bladder cancer	0.000869	0.000988	CcSEcCtD
Fosaprepitant—Body temperature increased—Etoposide—urinary bladder cancer	0.000869	0.000988	CcSEcCtD
Fosaprepitant—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000869	0.000988	CcSEcCtD
Fosaprepitant—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000869	0.000988	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—urinary bladder cancer	0.000866	0.000985	CcSEcCtD
Fosaprepitant—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000866	0.000985	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—urinary bladder cancer	0.000864	0.000982	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000863	0.000981	CcSEcCtD
Fosaprepitant—Asthenia—Cisplatin—urinary bladder cancer	0.000861	0.000979	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00086	0.000978	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000856	0.000974	CcSEcCtD
Fosaprepitant—Haematuria—Doxorubicin—urinary bladder cancer	0.000852	0.000969	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000852	0.000969	CcSEcCtD
Fosaprepitant—Urethral disorder—Epirubicin—urinary bladder cancer	0.00085	0.000967	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—urinary bladder cancer	0.000841	0.000956	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—urinary bladder cancer	0.000837	0.000952	CcSEcCtD
Fosaprepitant—Dizziness—Fluorouracil—urinary bladder cancer	0.000837	0.000952	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000835	0.00095	CcSEcCtD
Fosaprepitant—Diarrhoea—Cisplatin—urinary bladder cancer	0.000821	0.000933	CcSEcCtD
Fosaprepitant—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00082	0.000932	CcSEcCtD
Fosaprepitant—Vomiting—Gemcitabine—urinary bladder cancer	0.000818	0.000931	CcSEcCtD
Fosaprepitant—Bradycardia—Doxorubicin—urinary bladder cancer	0.000817	0.000929	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—urinary bladder cancer	0.000812	0.000923	CcSEcCtD
Fosaprepitant—Rash—Gemcitabine—urinary bladder cancer	0.000812	0.000923	CcSEcCtD
Fosaprepitant—Dermatitis—Gemcitabine—urinary bladder cancer	0.000811	0.000922	CcSEcCtD
Fosaprepitant—Eye disorder—Epirubicin—urinary bladder cancer	0.00081	0.000922	CcSEcCtD
Fosaprepitant—Hypersensitivity—Etoposide—urinary bladder cancer	0.00081	0.000921	CcSEcCtD
Fosaprepitant—Tinnitus—Epirubicin—urinary bladder cancer	0.000809	0.000919	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—urinary bladder cancer	0.000807	0.000917	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—urinary bladder cancer	0.000807	0.000917	CcSEcCtD
Fosaprepitant—Headache—Gemcitabine—urinary bladder cancer	0.000806	0.000917	CcSEcCtD
Fosaprepitant—Flushing—Epirubicin—urinary bladder cancer	0.000805	0.000915	CcSEcCtD
Fosaprepitant—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000805	0.000915	CcSEcCtD
Fosaprepitant—Vomiting—Fluorouracil—urinary bladder cancer	0.000805	0.000915	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000798	0.000908	CcSEcCtD
Fosaprepitant—Rash—Fluorouracil—urinary bladder cancer	0.000798	0.000907	CcSEcCtD
Fosaprepitant—Dermatitis—Fluorouracil—urinary bladder cancer	0.000797	0.000907	CcSEcCtD
Fosaprepitant—Headache—Fluorouracil—urinary bladder cancer	0.000793	0.000902	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000792	0.000901	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—urinary bladder cancer	0.00079	0.000898	CcSEcCtD
Fosaprepitant—Asthenia—Etoposide—urinary bladder cancer	0.000789	0.000897	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000789	0.000897	CcSEcCtD
Fosaprepitant—Angiopathy—Epirubicin—urinary bladder cancer	0.000787	0.000895	CcSEcCtD
Fosaprepitant—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000787	0.000894	CcSEcCtD
Fosaprepitant—Immune system disorder—Epirubicin—urinary bladder cancer	0.000783	0.000891	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000782	0.000889	CcSEcCtD
Fosaprepitant—Pruritus—Etoposide—urinary bladder cancer	0.000778	0.000884	CcSEcCtD
Fosaprepitant—Nausea—Gemcitabine—urinary bladder cancer	0.000765	0.000869	CcSEcCtD
Fosaprepitant—Vomiting—Cisplatin—urinary bladder cancer	0.000763	0.000867	CcSEcCtD
Fosaprepitant—Mental disorder—Epirubicin—urinary bladder cancer	0.00076	0.000864	CcSEcCtD
Fosaprepitant—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000759	0.000863	CcSEcCtD
Fosaprepitant—Rash—Cisplatin—urinary bladder cancer	0.000757	0.00086	CcSEcCtD
Fosaprepitant—Dermatitis—Cisplatin—urinary bladder cancer	0.000756	0.000859	CcSEcCtD
Fosaprepitant—Erythema—Epirubicin—urinary bladder cancer	0.000755	0.000858	CcSEcCtD
Fosaprepitant—Malnutrition—Epirubicin—urinary bladder cancer	0.000755	0.000858	CcSEcCtD
Fosaprepitant—Diarrhoea—Etoposide—urinary bladder cancer	0.000752	0.000855	CcSEcCtD
Fosaprepitant—Nausea—Fluorouracil—urinary bladder cancer	0.000752	0.000855	CcSEcCtD
Fosaprepitant—Eye disorder—Doxorubicin—urinary bladder cancer	0.00075	0.000853	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000749	0.000851	CcSEcCtD
Fosaprepitant—Tinnitus—Doxorubicin—urinary bladder cancer	0.000748	0.000851	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—urinary bladder cancer	0.000746	0.000848	CcSEcCtD
Fosaprepitant—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000745	0.000847	CcSEcCtD
Fosaprepitant—Flushing—Doxorubicin—urinary bladder cancer	0.000745	0.000847	CcSEcCtD
Fosaprepitant—Flatulence—Epirubicin—urinary bladder cancer	0.000744	0.000846	CcSEcCtD
Fosaprepitant—Dysgeusia—Epirubicin—urinary bladder cancer	0.000739	0.000841	CcSEcCtD
Fosaprepitant—Angiopathy—Doxorubicin—urinary bladder cancer	0.000728	0.000828	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—urinary bladder cancer	0.000728	0.000827	CcSEcCtD
Fosaprepitant—Dizziness—Etoposide—urinary bladder cancer	0.000727	0.000826	CcSEcCtD
Fosaprepitant—Muscle spasms—Epirubicin—urinary bladder cancer	0.000726	0.000825	CcSEcCtD
Fosaprepitant—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000725	0.000824	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000723	0.000822	CcSEcCtD
Fosaprepitant—Nausea—Cisplatin—urinary bladder cancer	0.000713	0.00081	CcSEcCtD
Fosaprepitant—Cough—Methotrexate—urinary bladder cancer	0.000704	0.0008	CcSEcCtD
Fosaprepitant—Mental disorder—Doxorubicin—urinary bladder cancer	0.000703	0.000799	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.0007	0.000796	CcSEcCtD
Fosaprepitant—Vomiting—Etoposide—urinary bladder cancer	0.000699	0.000795	CcSEcCtD
Fosaprepitant—Malnutrition—Doxorubicin—urinary bladder cancer	0.000699	0.000794	CcSEcCtD
Fosaprepitant—Erythema—Doxorubicin—urinary bladder cancer	0.000699	0.000794	CcSEcCtD
Fosaprepitant—Anaemia—Epirubicin—urinary bladder cancer	0.000698	0.000793	CcSEcCtD
Fosaprepitant—Rash—Etoposide—urinary bladder cancer	0.000693	0.000788	CcSEcCtD
Fosaprepitant—Dermatitis—Etoposide—urinary bladder cancer	0.000692	0.000787	CcSEcCtD
Fosaprepitant—Headache—Etoposide—urinary bladder cancer	0.000689	0.000783	CcSEcCtD
Fosaprepitant—Flatulence—Doxorubicin—urinary bladder cancer	0.000688	0.000783	CcSEcCtD
Fosaprepitant—Chest pain—Methotrexate—urinary bladder cancer	0.000687	0.000781	CcSEcCtD
Fosaprepitant—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000684	0.000778	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000682	0.000776	CcSEcCtD
Fosaprepitant—Malaise—Epirubicin—urinary bladder cancer	0.000681	0.000774	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—urinary bladder cancer	0.000679	0.000772	CcSEcCtD
Fosaprepitant—Syncope—Epirubicin—urinary bladder cancer	0.000677	0.00077	CcSEcCtD
Fosaprepitant—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000672	0.000764	CcSEcCtD
Fosaprepitant—Palpitations—Epirubicin—urinary bladder cancer	0.000667	0.000759	CcSEcCtD
Fosaprepitant—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000664	0.000754	CcSEcCtD
Fosaprepitant—Cough—Epirubicin—urinary bladder cancer	0.000659	0.000749	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000658	0.000749	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—urinary bladder cancer	0.000654	0.000744	CcSEcCtD
Fosaprepitant—Nausea—Etoposide—urinary bladder cancer	0.000653	0.000742	CcSEcCtD
Fosaprepitant—Hypertension—Epirubicin—urinary bladder cancer	0.000652	0.000741	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000648	0.000737	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000646	0.000734	CcSEcCtD
Fosaprepitant—Anaemia—Doxorubicin—urinary bladder cancer	0.000646	0.000734	CcSEcCtD
Fosaprepitant—Chest pain—Epirubicin—urinary bladder cancer	0.000643	0.000731	CcSEcCtD
Fosaprepitant—Anxiety—Epirubicin—urinary bladder cancer	0.000641	0.000728	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—urinary bladder cancer	0.00064	0.000727	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000638	0.000726	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000637	0.000724	CcSEcCtD
Fosaprepitant—Discomfort—Epirubicin—urinary bladder cancer	0.000635	0.000722	CcSEcCtD
Fosaprepitant—Malaise—Doxorubicin—urinary bladder cancer	0.00063	0.000716	CcSEcCtD
Fosaprepitant—Dry mouth—Epirubicin—urinary bladder cancer	0.000629	0.000715	CcSEcCtD
Fosaprepitant—Syncope—Doxorubicin—urinary bladder cancer	0.000626	0.000712	CcSEcCtD
Fosaprepitant—Palpitations—Doxorubicin—urinary bladder cancer	0.000617	0.000702	CcSEcCtD
Fosaprepitant—Oedema—Epirubicin—urinary bladder cancer	0.000616	0.000701	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000616	0.000701	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—urinary bladder cancer	0.000615	0.0007	CcSEcCtD
Fosaprepitant—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000614	0.000698	CcSEcCtD
Fosaprepitant—Infection—Epirubicin—urinary bladder cancer	0.000612	0.000696	CcSEcCtD
Fosaprepitant—Cough—Doxorubicin—urinary bladder cancer	0.00061	0.000693	CcSEcCtD
Fosaprepitant—Shock—Epirubicin—urinary bladder cancer	0.000606	0.000689	CcSEcCtD
Fosaprepitant—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000604	0.000687	CcSEcCtD
Fosaprepitant—Hypertension—Doxorubicin—urinary bladder cancer	0.000603	0.000686	CcSEcCtD
Fosaprepitant—Skin disorder—Epirubicin—urinary bladder cancer	0.000598	0.00068	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000596	0.000677	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—urinary bladder cancer	0.000596	0.000677	CcSEcCtD
Fosaprepitant—Chest pain—Doxorubicin—urinary bladder cancer	0.000595	0.000676	CcSEcCtD
Fosaprepitant—Anxiety—Doxorubicin—urinary bladder cancer	0.000593	0.000674	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000591	0.000672	CcSEcCtD
Fosaprepitant—Discomfort—Doxorubicin—urinary bladder cancer	0.000588	0.000668	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—urinary bladder cancer	0.000587	0.000667	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—urinary bladder cancer	0.000585	0.000666	CcSEcCtD
Fosaprepitant—Dry mouth—Doxorubicin—urinary bladder cancer	0.000582	0.000661	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—urinary bladder cancer	0.00058	0.000659	CcSEcCtD
Fosaprepitant—Hypotension—Epirubicin—urinary bladder cancer	0.000576	0.000655	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—urinary bladder cancer	0.000572	0.000651	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00057	0.000648	CcSEcCtD
Fosaprepitant—Oedema—Doxorubicin—urinary bladder cancer	0.00057	0.000648	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000568	0.000646	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—urinary bladder cancer	0.000568	0.000645	CcSEcCtD
Fosaprepitant—Infection—Doxorubicin—urinary bladder cancer	0.000566	0.000644	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—urinary bladder cancer	0.000563	0.00064	CcSEcCtD
Fosaprepitant—Shock—Doxorubicin—urinary bladder cancer	0.000561	0.000638	CcSEcCtD
Fosaprepitant—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000559	0.000636	CcSEcCtD
Fosaprepitant—Insomnia—Epirubicin—urinary bladder cancer	0.000557	0.000634	CcSEcCtD
Fosaprepitant—Skin disorder—Doxorubicin—urinary bladder cancer	0.000554	0.00063	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000551	0.000627	CcSEcCtD
Fosaprepitant—Dyspnoea—Epirubicin—urinary bladder cancer	0.000549	0.000625	CcSEcCtD
Fosaprepitant—Somnolence—Epirubicin—urinary bladder cancer	0.000548	0.000623	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000543	0.000617	CcSEcCtD
Fosaprepitant—Dyspepsia—Epirubicin—urinary bladder cancer	0.000542	0.000617	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000538	0.000612	CcSEcCtD
Fosaprepitant—Decreased appetite—Epirubicin—urinary bladder cancer	0.000536	0.000609	CcSEcCtD
Fosaprepitant—Hypotension—Doxorubicin—urinary bladder cancer	0.000533	0.000606	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000532	0.000605	CcSEcCtD
Fosaprepitant—Fatigue—Epirubicin—urinary bladder cancer	0.000531	0.000604	CcSEcCtD
Fosaprepitant—Pain—Epirubicin—urinary bladder cancer	0.000527	0.000599	CcSEcCtD
Fosaprepitant—Constipation—Epirubicin—urinary bladder cancer	0.000527	0.000599	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—urinary bladder cancer	0.000523	0.000595	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—urinary bladder cancer	0.00052	0.000592	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—urinary bladder cancer	0.00052	0.000592	CcSEcCtD
Fosaprepitant—Insomnia—Doxorubicin—urinary bladder cancer	0.000516	0.000586	CcSEcCtD
Fosaprepitant—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000508	0.000578	CcSEcCtD
Fosaprepitant—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000508	0.000577	CcSEcCtD
Fosaprepitant—Somnolence—Doxorubicin—urinary bladder cancer	0.000507	0.000576	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000504	0.000573	CcSEcCtD
Fosaprepitant—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000502	0.000571	CcSEcCtD
Fosaprepitant—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000496	0.000564	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000492	0.00056	CcSEcCtD
Fosaprepitant—Fatigue—Doxorubicin—urinary bladder cancer	0.000492	0.000559	CcSEcCtD
Fosaprepitant—Urticaria—Epirubicin—urinary bladder cancer	0.000489	0.000557	CcSEcCtD
Fosaprepitant—Pain—Doxorubicin—urinary bladder cancer	0.000488	0.000554	CcSEcCtD
Fosaprepitant—Constipation—Doxorubicin—urinary bladder cancer	0.000488	0.000554	CcSEcCtD
Fosaprepitant—Abdominal pain—Epirubicin—urinary bladder cancer	0.000487	0.000554	CcSEcCtD
Fosaprepitant—Body temperature increased—Epirubicin—urinary bladder cancer	0.000487	0.000554	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000485	0.000552	CcSEcCtD
Fosaprepitant—Asthenia—Methotrexate—urinary bladder cancer	0.000472	0.000537	CcSEcCtD
Fosaprepitant—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00047	0.000534	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000466	0.00053	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—urinary bladder cancer	0.000466	0.00053	CcSEcCtD
Fosaprepitant—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000454	0.000516	CcSEcCtD
Fosaprepitant—Urticaria—Doxorubicin—urinary bladder cancer	0.000453	0.000515	CcSEcCtD
Fosaprepitant—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000451	0.000512	CcSEcCtD
Fosaprepitant—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000451	0.000512	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—urinary bladder cancer	0.00045	0.000512	CcSEcCtD
Fosaprepitant—Asthenia—Epirubicin—urinary bladder cancer	0.000442	0.000503	CcSEcCtD
Fosaprepitant—Pruritus—Epirubicin—urinary bladder cancer	0.000436	0.000496	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—urinary bladder cancer	0.000435	0.000495	CcSEcCtD
Fosaprepitant—Diarrhoea—Epirubicin—urinary bladder cancer	0.000422	0.000479	CcSEcCtD
Fosaprepitant—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00042	0.000478	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—urinary bladder cancer	0.000419	0.000476	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—urinary bladder cancer	0.000415	0.000472	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—urinary bladder cancer	0.000415	0.000472	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—urinary bladder cancer	0.000412	0.000469	CcSEcCtD
Fosaprepitant—Asthenia—Doxorubicin—urinary bladder cancer	0.000409	0.000465	CcSEcCtD
Fosaprepitant—Dizziness—Epirubicin—urinary bladder cancer	0.000407	0.000463	CcSEcCtD
Fosaprepitant—Pruritus—Doxorubicin—urinary bladder cancer	0.000403	0.000459	CcSEcCtD
Fosaprepitant—Vomiting—Epirubicin—urinary bladder cancer	0.000392	0.000445	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—urinary bladder cancer	0.000391	0.000445	CcSEcCtD
Fosaprepitant—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00039	0.000444	CcSEcCtD
Fosaprepitant—Rash—Epirubicin—urinary bladder cancer	0.000389	0.000442	CcSEcCtD
Fosaprepitant—Dermatitis—Epirubicin—urinary bladder cancer	0.000388	0.000441	CcSEcCtD
Fosaprepitant—Headache—Epirubicin—urinary bladder cancer	0.000386	0.000439	CcSEcCtD
Fosaprepitant—Dizziness—Doxorubicin—urinary bladder cancer	0.000377	0.000429	CcSEcCtD
Fosaprepitant—Nausea—Epirubicin—urinary bladder cancer	0.000366	0.000416	CcSEcCtD
Fosaprepitant—Vomiting—Doxorubicin—urinary bladder cancer	0.000362	0.000412	CcSEcCtD
Fosaprepitant—Rash—Doxorubicin—urinary bladder cancer	0.000359	0.000409	CcSEcCtD
Fosaprepitant—Dermatitis—Doxorubicin—urinary bladder cancer	0.000359	0.000408	CcSEcCtD
Fosaprepitant—Headache—Doxorubicin—urinary bladder cancer	0.000357	0.000406	CcSEcCtD
Fosaprepitant—Nausea—Doxorubicin—urinary bladder cancer	0.000339	0.000385	CcSEcCtD
